NVAX Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Strategic Partnership ExpansionBroad, nonexclusive partnerships with Pfizer, Sanofi and four new MTAs (including a top‑10 oncology company) diversify development and commercialization pathways. This reduces single‑product dependence, spreads R&D risk across partners and creates multiple potential milestone and royalty streams over years.
Partner-driven Revenue Growth & Matrix‑M AdoptionRapid growth in partner‑sourced revenue (supply sales and licensing/royalties) signals durable commercial traction for Novavax's protein platform and Matrix‑M adjuvant. Partner monetization provides recurring, less capital‑intensive revenue streams that can underpin margins and reduce reliance on direct product commercial execution.
Large Cash + Nondilutive Funding RunwayA reported $818M cash/AR balance plus $80M nondilutive inflows (Pfizer upfront, credit draw) materially extends runway into 2028 per management. This reduces immediate refinancing and dilution pressure, giving time to convert MTAs, realize milestones and advance prioritized programs before new equity is needed.
Bears Say
Negative Shareholders' EquityPersistently negative shareholders' equity constrains financial flexibility and weakens the cushion against losses. It makes leverage metrics less meaningful, increases creditor scrutiny, and raises the probability that weaker operating results would force dilutive financing or unfavorable refinancing terms over the medium term.
Weak Operating Cash GenerationSustained negative operating and free cash flow reflects real cash burn, not merely accounting losses. Continued outflows heighten dependency on partner payments or external financing to fund operations, and prolong the period before internal cash generation can sustainably fund R&D and commercialization investments.
Low Direct Sales And Dependence On Partner ConversionDirect product sales are currently small and much future revenue hinges on partners converting MTAs to licenses and executing development/commercial plans. That timing and conversion rate are uncertain, making revenue visibility brittle and exposing Novavax to partner execution, clinical and commercial risk over the medium term.
Novavax News
NVAX FAQ
What was Novavax’s price range in the past 12 months?
Currently, no data Available
What is Novavax’s market cap?
Novavax’s market cap is CHF1.25B.
When is Novavax’s upcoming earnings report date?
Novavax’s upcoming earnings report date is Aug 12, 2026 which is in 32 days.
How were Novavax’s earnings last quarter?
Novavax released its earnings results on May 06, 2026. The company reported -$0.048 earnings per share for the quarter, beating the consensus estimate of -$0.196 by $0.147.
Is Novavax overvalued?
According to Wall Street analysts Novavax’s price is currently Undervalued.
Does Novavax pay dividends?
Novavax does not currently pay dividends.
What is Novavax’s EPS estimate?
Novavax’s EPS estimate is -0.32.
How many shares outstanding does Novavax have?
Currently, no data Available
What happened to Novavax’s price movement after its last earnings report?
Novavax reported an EPS of -$0.048 in its last earnings report, beating expectations of -$0.196. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Novavax?
Currently, no hedge funds are holding shares in CH:NVAX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Novavax Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
CHF9.50 (― Downside)
CHF9.50 (― Downside)
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
33.52%
12-Months-Change
Fundamentals
Return on Equity
89.73%
Trailing 12-Months
Asset Growth
-19.32%
Trailing 12-Months
Company Description
Novavax
Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.
NVAX Company Deck
NVAX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong strategic progress: rapid expansion of partner collaborations, material partner-driven revenue growth, improved cash position and meaningful reductions in operating costs. Management showcased encouraging preclinical data (notably for a prioritized C. difficile asset) and reiterated 2026 guidance while outlining a credible path to non-GAAP profitability by 2028. Near-term challenges include a large YoY revenue decline driven by a prior-period noncash item, modest direct product sales, continued reliance on partners to convert MTAs to licensed programs and some near-term expense support for partners. On balance, the highlights—particularly partnership momentum, partner-revenue growth, cash runway and cost reductions—substantially outweigh the lowlights, though execution and timing risks remain.View all CH:NVAX earnings summariesNVAX Stock 12 Month Forecast
Average Price Target
$9.50
Vir Biotechnology
―
Oric Pharmaceuticals
―
―
AbCellera Biologics
―
Sana Biotechnology
―
Options Prices
Currently, No data available
---